Bisphosphonates and atrial fibrillation: Clinical trial data suggest possible link

Prescrire International

Volumn 20, Issue 115, 2011, Pages 96-97

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ARTHRALGIA; ARTICLE; BONE NECROSIS; CANCER PATIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; ESOPHAGUS CANCER; FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; JAW OSTEONECROSIS; MEDICAL PRACTICE; MYALGIA; OBSERVATIONAL STUDY; PAGET BONE DISEASE; POSTMENOPAUSE; RISK FACTOR; TREATMENT DURATION;

ATRIAL FIBRILLATION; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; OSTEOPOROSIS; RISK; SEVERITY OF ILLNESS INDEX;

EID: 79953240315     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Prescrire Editorial Staff "Ostonecrosis of the jaw due to bisphosphonates" Prescrire Int 2008; 17 (97): 202-203.
2. Prescrire Rédaction "Patients ayant une osté oporose" Rev Prescrire 2010; 30 (326 suppl. interactions médicamenteuses).
3. Prescrire Editorial Staff "Bisphosphonates and atrial fibrillation" Prescrire Int 2008; 17 (96): 161.
4. Bhuriya R et al. "Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis" Int J Cardiol 2010; 142 (3): 213-217.
5. Mak A et al. "Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies" BMC Musculoskelet Disord 2009; 10: 113.
6. Loke YK et al. "Bisphosphonates and atrial fibrillation-Systematic review and meta-analysis" Drug Saf 2009; 32 (3): 219-228.
7. Miranda J et al. "A meta-analysis of the risk of atrial fibrillation in bisphosphonate users" Chest 2008. meeting.chestjournal.org accessed 7 November 2008.
8. Kim SY et al. "Biphosphonates and risk of atrial fibrillation: a meta-analysis" Arthritis Res Ther 2010; 12 (1): R30.
9. Erra A et al. "Fibrilación auricular y ácido zoledrónico en la enfermedad de Paget" Reumatol Clin 2008; 4 (4): 166-167.
10. Sorensen HT et al. "Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study" BMJ 2008; 336 (7648): 813-816. (Pubitemid 351548223)
11. Heckbert SR et al. "Use of alendronate and risk of incident atrial fibrillation in women" Arch Intern Med 2008; 168 (8): 826-831. (Pubitemid 351649266)
12. Abrahamsen B et al. "Atrial fibrillation in fracture patients treated with oral biphosphonates" J Int Med 2009; 265 (5): 581-592.
13. Black DM et al. "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis" N Engl J Med 2007; 356 (18): 1809-1822. (Pubitemid 46698462)
14. Karam R et al. "Yearly zoledronic acid in post-menopausal osteoporosis" N Engl J Med 2007; 357 (7): 711-713.
15. Papapoulous S et al. "Ibandronate is not associated with an increased risk of atrial fibrillation: an assessment by annual cumulative exposure in pivotal trials" Ann Rheum Dis 2008; 67: 538.
16. Prescrire Editorial Staff "Do not use bisphosphonate therapy indefinitely for fracture prevention" Prescrire Int 2008; 17 (97): 214.
17. Prescrire Editorial Staff "meta-analyses of mammography screening trials: inconsistent results" Prescrire Int 2006; 15 (85): 192-193.
18. "Bisphosphonates". In: "Martindale The Complete Drug Reference" The Pharmaceutical Press, London. www.medicinescomplete.com accessed 5 May 2010: 18 pages.